## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Farzan Rastinejad et al. :

APPLICATION NO.: 09/443,542 : Examiner: Gregory W. Mitchell

FILING DATE: November 19, 1999 : Group Art Unit: 1617

TITLE: METHODS AND COMPOSITIONS FOR:

RESTORING CONFORMATIONAL STABILITY OF A PROTEIN OF THE p53

**FAMILY** 

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

V.

## Inventor Declaration under 37 CFR 1.132

I, Dr. Farzan Rastinejad, an inventor on the above-identified application, make this declaration in support thereof.

I received my Ph.D. degree from Northwestern University, Chicago, Illinois, in 1988. For the last eleven (11) years, I have been employed by Pfizer, Inc. where I am Senior Principal Investigator for Oncology.

The attached data printout sheets show the results of testing (according to the general protocol of Example 1 of the present application) of compounds to determine their efficacy in stabilizing the native conformation of p53. In Panel I of the printout (Pages1-9), the "SC50" value ("stabilizing concentration") represents the concentration of the test compound (usually micromolar, unless the compound is reported as inactive or weekly inactive) needed to retain (per the Example 1 protocol) 50% of maximal binding of a p53-specific antibody whose binding to p53 is conformationally dependent (for non denatured p53). The periods of incubation vary somewhat, since the data was intended to be qualitative, useful for a broad comparison, but are generally about 30 minutes at about 37 degrees C.

The data evidence a wide variety of chemical compounds that bind to p53 and can stabilize it, including many as disclosed in the above-identified patent application. The data panels show a complete listing of all compounds tested in the panel, including large umbers of compounds that are not effective in the practice of the invention. Similarly, Panel 2 of the printout (the subsequently following Pages 1-33) shows additional compounds having activity according to the practice of the invention (again as measured by SC50, data in far right column), and the inactive compounds of this subsequent panel are also shown. The lack of a number in the far right hand column means that the compound was inactive.

I acknowledge that all statements made of my own knowledge, are true and that all statements made on information and belief are believed to be true.

I further acknowledge that willful false statements, and the like, are punishable by fine or imprisonment, or both (18 USC section 1001) and may jeopardize the validity of the application or any patents issuing thereon.


Dated:	
	Dr. Farzan Rastineiad



MOLSTRUCTURE	SC50 (uM)	MOLSTRUCTURE	SC50 (uM)
F CH <sub>3</sub>	7	CH <sub>1</sub>	7
CH <sub>3</sub>	50	H <sub>3</sub> C H <sub>3</sub> C N CH <sub>3</sub>	9
O N CH,	53	pH, on cH,	10
OH OH	54		13
H <sub>3</sub> C N CH <sub>3</sub> N	59		16
		HO OH	17
HO N N N N N N N N N N N N N N N N N N N	100	H.C. W. CH.	19
	100		23
CH <sub>3</sub>	120	H <sub>2</sub> C-A <sub>2</sub> CH <sub>3</sub>	23
H <sub>2</sub> C N	120		32
	120		36
CH <sub>3</sub>	150		36

H <sub>3</sub> C <sup>-0</sup> CH <sub>3</sub>	180	a CH <sub>3</sub>	57
H,C-0	220	N H,C CH,	94
	220		WEAK
H <sub>3</sub> C CH <sub>3</sub>	240	CH <sub>3</sub> O N N N O H,C N O N O O H	INACTIVE
	280	N N N N N N N N N N N N N N N N N N N	INACTIVE
	WEAK(300)		INACTIVE
	WEAK(430)		INACTIVE
	WEAK	H,G CH,	WEAK
O . CH <sup>3</sup>	WEAK	Br N N N N N N N N N N N N N N N N N N N	WEAK
	WEAK	CH, CH,	WEAK
	WEAK		WEAK
	WEAK		WEAK
	WEAK		INACTIVE

	WEAK-IN	The second secon	INACTIVE
HO O	WEAK-IN	Br Hy O OH,	INACTIVE
	WEAK-IN	H <sub>3</sub> C, CH <sub>3</sub>	WEAK
HOO	WEAK-IN		INACTIVE
H,C.O	WEAK-IN		INACTIVE
PH <sub>3</sub>	WEAK-IN	03 N N N O -	INACTIVE
CH <sub>3</sub> O-CH <sub>3</sub>	WEAK-IN	H,C CH,	WEAK
H <sub>3</sub> C O	WEAK-IN	H.C CH, DI,	INACTIVE
		CH <sub>s</sub>	INACTIVE
		H.C. H.C.	INACTIVE
		Br N N N	INACTIVE
		H <sub>2</sub> N—	INACTIVE
			INACTIVE



INACTIVE

#OLSTRUCTURE	SC50 (uM	) MOLSTRUCTURE	SC50 (uM)
	4		
	5	H <sub>3</sub> C <sup>O</sup> NH <sub>3</sub>	130
S H,C CH,	8	N, CH <sub>3</sub> CH <sub>3</sub>	INACTIVE
	9	O'CH,	INACTIVE
H. C. C.	10	он но	INACTIVE
	11	CH <sub>3</sub> O-S <sub>0</sub> CH <sub>3</sub>	INACTIVE
S-CH,	12	CH <sub>3</sub> O <sub>1</sub> S <sub>3</sub> CH <sub>3</sub>	WEAK
	16	H <sub>3</sub> C N	INACTIVE
S TO CH,	23		INACTIVE
	25	CH <sub>3</sub>	INACTIVE
PH.	31		
H.CCC.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.	36		

	36		INACTIVE
CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub>	38	CH <sub>3</sub>	INACTIVE
	42	ОТ	INACTIVE
	44	CH <sub>3</sub>	WEAK-IN.
CH <sub>b</sub>	67	CH,	INACTIVE
N S	INACTIVE	CH <sub>3</sub>	INACTIVE
	WEAK	NH <sub>2</sub>	WEAK
T T T T T T T T T T T T T T T T T T T	WEAK	CH, CH,	INACTIVE
	INACTIVE		WEAK
	INACTIVE	C N-CH,	INACTIVE
	INACTIVE	N-CH,	INACTIVE
S O CH <sub>3</sub>	INACTIVE	CH <sub>3</sub>	INACTIVE
	WEAK-IN.	CH,	INACTIVE

	WEAK	INACTIVE
+0-12°00000000000000000000000000000000000	INACTIVE NO CH, CH,	WEAK
CH <sub>3</sub>	INACTIVE TN CH3	INACTIVE
	INACTIVE S S S CH, CH,	INACTIVE
) O-N-O-CH3	INACTIVE NO NO CHA	INACTIVE
	INACTIVE STORY	INACTIVE
	INACTIVE OH	INACTIVE
S CH,	INACTIVE H,C., NCH,	INACTIVE
CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub>	INACTIVE CH,	INACTIVE
	INACTIVE	
	INACTIVE	
N CH,	WEAK MOLSTRUCTURE	SC50 (uM)
S CH <sub>3</sub>	WEAK TITE	INACTIVE

H <sub>3</sub> C O	INACTIVE	N-CH <sub>3</sub>	INACTIVE
	INACTIVE	H <sub>3</sub> C, N N N N	INACTIVE
H <sub>a</sub> C'O	INACTIVE		INACTIVE
	INACTIVE	ON NH2	INACTIVE
H <sub>3</sub> C-O	WEAK	N. CH3	INACTIVE
O. CH.	WEAK	NH <sub>2</sub> N N CH <sub>3</sub>	INACTIVE
о · сн,	WEAK	NH <sub>2</sub> N O CH <sub>3</sub> H <sub>3</sub> C	INACTIVE
н,с о	INACTIVE	N. N	INACTIVE
	INACTIVE	H <sub>2</sub> C-O NH <sub>2</sub>	INACTIVE
	WEAK-IN.	O-N-O N-CH3	INACTIVE
H <sub>G</sub> CH <sub>3</sub>	WEAK	H <sub>3</sub> C- CH <sub>3</sub> CH <sub>3</sub> N CH <sub>3</sub>	INACTIVE
	INACTIVE	H <sub>3</sub> C CH <sub>3</sub>	INACTIVE
BHSU.OH OH O-OH,	WEAK		INACTIVE

pfizer.number	molstructure	picks	SC50 (uM)
	·ÇĞ	х	
		X	
		х	
		x	
	P N N N N N N N N N N N N N N N N N N N		

	S S S S S S S S S S S S S S S S S S S		
	N N N N N N N N N N N N N N N N N N N	X	
	N N N N N N N N N N N N N N N N N N N		
	Orient Chiral		
		Х	
		X	
·			
		Х	
		X	

		30
	X	
100 N	Х	
	Х	
	X	
	Х	

			 <del></del>
		<b>.</b>	
,			
		K	
	F N N N		
	F N N N		
	+12~~		
	+		

	×	
F-F-F		

٠.	F F F F F F F F F F F F F F F F F F F		
		-	·
	79		
	1. O		
	\$ \$		

	4		
· · ·	\$ 0.50		
	CI CI		
	*		
	707		
	N F F		

N N F		
N N F		
	×	
F N N F F		
N F		
~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~		
N N F		

N N F F		
F F		
N N F F		
C) X		
N N N F		
Chiral N N N N F F		
N N P F		

)

F N N N N N N N N N N N N N N N N N N N		,	
ON N F F			
SN FF			
N N N F F	×		
N N F F			
N N N N F F			

 	п -	 
N N N F F		
N N F F		
N N N F F		
N N N F F	X	
N N F F		
N N F		
A A A		
N N F F		
	X	

Ş. XXX		
\$		
 ×		

\$ ****		
FINN		
×		
F N N N C C C C C C C C C C C C C C C C	×	
**************************************	7	
F N N N F		
F N N O O		
<i>*</i>		

	, y'		
·	***		
	·		
	F N N N F F		
·	F N N CI		
	***		
	F N N N F		
	itil of		

	,i,Q	:	
	· / , " ·		
			1
·			
	<b>\(\frac{1}{2}\)</b>		
	<u> </u>	-	
		···-	
	\$		-
	×\$\$\$		
	, (X)		
	,X, ~ ~		
	\$		
	X		
	,,		
,			
	C <sub>1</sub>		
	,	_	

***		
	-	·

		·
		·

			·
	**************************************		
	<del>, , , , , , , , , , , , , , , , , , , </del>		
·	70,70		

	+Q-1-10 -{		
	<b>A</b>		
,	<del>4</del>		
	500		
	& San		
	tago		
	·	<del></del>	 

	5,			
			·	
				22
L	1	<u> </u>	<u> </u>	<u> </u>

·			
			-
	, mo		
	\$200 \$2		
	Ping O		
	*/		

	x	
X,		
to the second		52
\$ ppp		
-{{}		50
	X	22
- D		

	П	 
	x	
	×	
		50
\.\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\		
**************************************		

 	 <del> </del>	
d j		
**************************************		
\$20. <sup>1</sup>		
		:

 	,		
<b>* * * * * * * * * *</b>			
\$\frac{1}{2}\frac{1}{2		-	
\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$			

**************************************		
+++		
Ç <del>T</del>		
İ,		
, XX, X		
<del></del>		60
Y X		
*****		
YYY,		
A A		
\$ ****		

	X-1-1-1
	' ' ' ' ' '
	"
	<u>U</u>
	Xxxx
	U
	FX_N_0
<u>                                 </u>	

F F N N O		
XXX;		
 744		
**************************************		·
~ ~ ~		
<del>****</del>		
F N Chiral		
XXX.		
**************************************		

·		<del></del>		
	F N N O N N N N N N N N N N N N N N N N			
	XX;			
	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\			
	\(\frac{1}{2}\)			
	S F N N			-
	, S			
			·	
	700			
	***************************************			
	Xxx;			
	\$ The state of the			
	<u>U</u>			

	****		
	**************************************		
	XXX;		
	Xxx;		
	**************************************		
	XXX;		·
	XXX;		
-	F / N / O		
	5		

 		,	
	,		
5			
5000			
4			

6		 	
	oro;		
	A CONTRACTOR OF THE CONTRACTOR		
	; \( \)		
	++		
	10 P		
	64		
	·£,		
	4		
	\$		

+077		
XX 0		
		55
oro,		